血清CCL24作为系统性硬化症纤维化与血管病变严重程度的生物标志物
在213例连续入组的系统性硬化症患者中,25.3%血清CCL24升高;高CCL24与男性、抗Scl-70阳性、间质性肺病、滑膜炎、指端溃疡、毛细血管扩张、钙质沉着及一氧化碳弥散量降低相关,并与更大肺功能下降和更高疾病相关死亡率相关。
要点
- 25.3%的系统性硬化症患者血清CCL24升高,高CCL24与男性、抗Scl-70阳性相关。
- 高CCL24患者间质性肺病、滑膜炎、指端溃疡、毛细血管扩张和钙质沉着更常见,一氧化碳弥散量更低。
- 纵向分析中,高CCL24与更大肺功能下降和更高疾病相关死亡率相关。
核心结论
- 血清CCL24是跨越纤维化和血管病变表现的系统性硬化症疾病严重程度的生物标志物。
- 这些数据支持开发靶向CCL24的疗法作为系统性硬化症的新型综合治疗靶点。
研究设计与样本
- 观察性队列研究,连续入组213例系统性硬化症患者,从血清评估之日起分析疾病进展和死亡率。
- 高CCL24截断值基于匹配的健康对照队列中的分布确定。
主要发现
- 中位病程6年(四分位距3-14),28.6%的患者有间质性肺病,46.9%有指端溃疡,25.3%血清CCL24浓度高。
- 高CCL24患者更常见男性、抗Scl-70阳性、间质性肺病和滑膜炎(所有P < 0.05)。
- 高CCL24患者一氧化碳弥散量更低,指端溃疡、毛细血管扩张和钙质沉着患病率更高(所有P < 0.05)。
- 纵向分析中,高CCL24与更大肺功能下降和更高疾病相关死亡率相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic sclerosis (SSc) is a heterogeneous disease, characterized by variable tissue and vascular fibrosis in the context of autoimmune activation. CCL24 (or Eotaxin2) has been shown to promote microangiopathic, proinflammatory, and profibrotic processes in preclinical models of SSc. Here, we study serum CCL24 levels in a real-life cohort of patients with SSc, to determine its distribution across disease features and its value in predicting disease progression and related mortality. METHODS: Serum CCL24 was assessed in an observational cohort of consecutively enrolled patients with SSc. A high CCL24 cutoff was defined based on its distribution in a matched cohort of healthy controls. Disease progression and mortality were analyzed from the date of serum assessment. RESULTS: Two-hundred thirteen consecutively enrolled patients with SSc were included in this analysis. Median disease duration was six years (interquartile range 3-14), 28.6% of patients presented with interstitial lung disease (ILD), 46.9% had digital ulcers, and 25.3% showed high CCL24 serum concentration. High-CCL24 patients were more frequently male and positive for anti-scl-70, with a diagnosis of ILD and synovitis (P < 0.05 for all). Notably, high-CCL24 patients had lower diffusion of carbon monoxide and higher prevalence of digital ulcers, telangiectasias, and calcinosis (P < 0.05 for all). In a longitudinal setting, high CCL24 was associated with greater lung function decline and with higher disease-related mortality. CONCLUSION: Serum CCL24 is a biomarker of disease severity across fibrotic and vascular disease manifestations. These data support the development of therapies targeting CCL24 as a novel comprehensive therapeutic target in SSc.
引用
- De Lorenzis E, Mor A, Ross RL, et al. Serum CCL24 as a Biomarker of Fibrotic and Vascular Disease Severity in Systemic Sclerosis. Arthritis Care Res (Hoboken). 2024. PMID: 38589291. doi:10.1002/acr.25344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。